nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.02.2022 | editorial

Toxicity management in severe and refractory cases—what we have learned

verfasst von: Univ.-Prof. Dr. Matthias Preusser

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

In this issue of the Magazine of European Medical Oncology (MEMO), we provide a series of articles summarizing data and discussing illustrative patient cases concerning the management of adverse events across oncological indications and affected organ systems. …

Vorheriger Artikel New frontiers in chronic lymphocytic leukemia on the way to curing the disease

Nächster Artikel Hepatocellular carcinoma—neoadjuvant systemic and local treatment concepts to improve resectability rates and oncological outcome

Pinter M, Scheiner B. Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab. memo. 2021; https://doi.org/10.1007/s12254-021-00747-9.CrossRef

Wass R, Lang D, Horner A, Lamprecht B. Checkpoint inhibitor pneumonitis: short review on literature and case report. memo. 2021; https://doi.org/10.1007/s12254-021-00756-8.CrossRef

Bergler-Klein J. Cardiotoxicity—current recommendations of prevention and treatment. memo. 2021; https://doi.org/10.1007/s12254-021-00766-6.CrossRef

Wolf P, Scherer T. Clinical challenges in the management of endocrine side effects of immune-oncological therapies. memo. 2021; https://doi.org/10.1007/s12254-021-00773-7.CrossRefPubMedPubMedCentral

Titel: Toxicity management in severe and refractory cases—what we have learned
verfasst von: Univ.-Prof. Dr. Matthias Preusser
Publikationsdatum: 01.02.2022
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 1/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-021-00788-0

Springer Medizin Österreich

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

Hepatocellular carcinoma—neoadjuvant systemic and local treatment concepts to improve resectability rates and oncological outcome

Treatment decision based on molecular profiling in metastatic colorectal cancer with a focus on RAS pathway mutations

Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab

Chronic myeloid leukemia associated with acquired von Willebrand syndrome: A case report

Cardiotoxicity—current recommendations of prevention and treatment

New actionable targets and investigational drugs in chronic lymphocytic leukemia